Breaking Down Livzon Pharmaceutical Group Inc. Financial Health: Key Insights for Investors

Curious whether Livzon Pharmaceutical Group Inc. (1513.HK) is a buy, hold or watch? The company reported operating income of RMB 3.18 billion in Q1 2025 (down 1.92% YoY) while net profit attributable to shareholders rose 4.75% to RMB 636.7 million, supporting a trailing twelve-month revenue of RMB 11.75 billion and gross profit of RMB 7.53 billion; profitability remains notable with a net profit margin of 17.79%, an operating margin of 27.02%, ROA (TTM) of 6.58% and ROE (TTM) of 15.53%, and EPS of RMB 0.71 for Q1 2025 (basic and diluted, +9.23% YoY) and RMB 1.96 for the nine months ending Sept 30, 2025 (+8.29% YoY). Balance-sheet and liquidity touchpoints show total assets of RMB 24.54 billion and equity attributable to shareholders of RMB 13.96 billion as of March 31, 2025, operating cash flow of RMB 2.53 billion for the first nine months of 2025 (+9.42% YoY) despite a 21.59% drop in net operating cash flow in Q1; capital actions include repurchasing 1,892,900 shares between April and June 2025 and an ordinary final cash dividend of RMB 11 per 10 shares payable July 11, 2025. On the strategic front, Livzon agreed in May 2025 to acquire a 64.81% stake in Imexpharm for VND 5.7 trillion to fund international expansion, while market valuation metrics as of July 1, 2025 show a market cap of CN¥30.18 billion, trailing P/E of 15.80, forward P/E of 14.48, P/S of 2.57 and P/B of 2.30, with EV/Revenue 2.25 and EV/EBITDA 8.53 and analyst forecasts of ~10.5% earnings and 5.8% revenue CAGR - risks include regulatory hurdles, currency and integration exposure, and competitive pressures, whereas opportunities span Vietnamese market access, R&D and AI adoption, and share repurchases; dive into the full breakdown for the detailed numbers and implications for investors.

Livzon Pharmaceutical Group Inc. (1513.HK) - Revenue Analysis

• Operating income (Q1 2025): RMB 3.18 billion, down 1.92% year-over-year.
• Net profit attributable to shareholders (Q1 2025): RMB 636.7 million, up 4.75% year-over-year.
• Total assets (as of March 31, 2025): RMB 24.54 billion, marginal increase from prior quarter.
• Revenue (TTM ending Mar 31, 2025): RMB 11.75 billion.
• Gross profit (TTM ending Mar 31, 2025): RMB 7.53 billion - indicating a stable gross margin.
• Operating revenue (9 months ending Sep 30, 2025): RMB 9.12 billion, up 0.38% YoY.

Key revenue drivers and context:

• Gross profit of RMB 7.53 billion on RMB 11.75 billion TTM revenue implies a gross margin ~64.0%, supporting margin resilience despite modest top-line growth.
• Q1 2025 operating income contraction (-1.92%) contrasted with net profit growth (+4.75%) suggests improved non-operating items, tax benefits, or cost control in other expense lines.
• Stable asset base (RMB 24.54 billion) provides scale for R&D and commercialization while limiting balance-sheet volatility.
• Sequential and YTD revenue trends (RMB 9.12 billion for 9M2025, +0.38% YoY) indicate near-flat growth; monitoring product mix and pricing will be critical for re-accelerating top-line expansion.

Livzon Pharmaceutical Group Inc. (1513.HK) - Profitability Metrics

Key profitability indicators for Livzon Pharmaceutical Group Inc. (1513.HK) show solid margins and improving earnings across recent reporting periods, supported by operational efficiency and asset returns.

• Net profit margin (TTM ending 2025-03-31): 17.79%
• Operating margin (TTM ending 2025-03-31): 27.02%
• Return on assets (ROA, TTM): 6.58%
• Return on equity (ROE, TTM): 15.53%
• Basic & diluted EPS (Q1 2025): RMB 0.71 - up 9.23% YoY
• EPS (9 months ending 2025-09-30): RMB 1.96 - up 8.29% YoY
• Profit margin trend: improved over nine months ending 2025-09-30

For additional corporate context, see: Livzon Pharmaceutical Group Inc.: History, Ownership, Mission, How It Works & Makes Money

Livzon Pharmaceutical Group Inc. (1513.HK) - Debt vs. Equity Structure

• Total liabilities (implied) = Total assets - Equity attributable to shareholders = RMB 24.54 bn - RMB 13.96 bn = RMB 10.58 bn.
• The company's debt-to-equity ratio is not explicitly stated in available sources; using implied liabilities as a proxy yields an approximate leverage metric: implied debt-to-equity ≈ 10.58 / 13.96 ≈ 0.76.
• Management has supplemented capital-return and balance-sheet policies via share repurchases and dividends.

• The Imexpharm acquisition (VND 5.7 trillion for 64.81%) is explicitly intended to be funded from internal resources, which may affect near-term cash balances and internal funding flexibility rather than increasing external indebtedness.
• Share repurchases (1,892,900 shares in Q2 2025) and the RMB 11 per 10 shares final cash dividend (FY2024) reflect active capital allocation to shareholders alongside M&A-driven internationalization.
• Investors should monitor: cash and cash equivalents, short-term borrowings, and post-acquisition financing/disclosure to reassess leverage and liquidity metrics once transaction funding and integration impacts are reported.

Livzon Pharmaceutical Group Inc. (1513.HK) - Liquidity and Solvency

Key metrics for Livzon Pharmaceutical Group Inc. illustrate a mixed short-term cash flow picture but a solid balance-sheet base as of early 2025.

• Operating cash flow for the first nine months of 2025: RMB 2.53bn, up 9.42% YoY - indicates improving cash generation over the trailing nine-month period.
• Q1 2025 net operating cash flow contraction: -21.59% - suggests quarter-specific pressures (seasonality, working capital movements or timing differences) that warrant monitoring.
• Balance-sheet scale: Total assets RMB 24.54bn vs equity RMB 13.96bn - equity covers more than half of assets, supporting solvency.
• Liquidity transparency: Management disclosures do not provide detailed liquidity ratios (current ratio, quick ratio) in available sources; investors should seek quarterly notes for working-capital specifics.
• Dividend policy: History of payouts with next payment scheduled for July 11, 2025 - supports cash-return track record.

Solvency assessment

• Equity cushion (RMB 13.96bn) and positive operating cash flow over nine months underpin solvency resilience.
• Short-term cash-flow volatility (Q1 decline) is a risk to watch; persistent declines could pressure liquidity despite strong equity.
• Continue monitoring: operating cash flow trends, disclosures on debt maturities, and any changes to dividend policy.

For broader context on investors and ownership dynamics, see: Exploring Livzon Pharmaceutical Group Inc. Investor Profile: Who's Buying and Why?

Livzon Pharmaceutical Group Inc. (1513.HK) - Valuation Analysis

• Market cap: CN¥30.18 billion (7/1/2025)
• Trailing P/E (TTM): 15.80
• Forward P/E (next FY): 14.48
• Price-to-Sales (TTM): 2.57
• Price-to-Book (MRQ): 2.30
• EV/Revenue: 2.25
• EV/EBITDA: 8.53
• Analyst consensus growth: Earnings +10.5% p.a.; Revenue +5.8% p.a.

• The trailing P/E of 15.8 and forward P/E of 14.48 indicate moderate earnings multiple - cheaper than high-growth biotechs but pricier than generics producers with weaker margins.
• Price-to-sales of 2.57 and EV/Revenue of 2.25 suggest the market places a premium on Livzon's revenue base relative to lower-margin peers.
• EV/EBITDA of 8.53 is within a range often viewed as reasonable for established pharmaceutical firms with stable cash flows.
• Analyst growth projections (earnings +10.5% and revenue +5.8% p.a.) support the forward multiple; if realized, multiples would be consistent with a fair-to-moderate valuation.

Livzon Pharmaceutical Group Inc. (1513.HK) - Risk Factors

• Regulatory and approval risk: Livzon operates in tightly regulated markets (China, ASEAN, selected export markets). Delays or non-approvals for key drugs (including NDAs, bioequivalence, GMP inspections) can materially affect near-term revenue recognition and launch timelines.
• Currency risk: Overseas operations and exports expose the company to FX volatility. Recent data indicate ~15-20% of group revenue is from international markets; a 5-10% depreciation of RMB or adverse moves in VND/USD could cut reported international revenue by a similar magnitude before hedging.
• Competitive pressure: Intense competition from domestic generics makers and large multinational pharma on innovative products may compress margins and market share, especially in crowded therapeutic classes.
• Integration risk from acquisitions (e.g., Imexpharm Corporation): M&A can bring operational, cultural and compliance integration issues, potential one-off costs, and temporary margin dilution if synergies underperform expectations.
• Pipeline and commercialization dependency: The company's growth depends on successful development and commercialization of new products. Clinical/regulatory setbacks or slower-than-expected uptake will hurt medium-term earnings momentum.
• Geopolitical exposure: Operations in or expansion toward ASEAN, emerging markets, and export relationships to Western markets carry risks from trade tensions, tariffs, sanctions, and shifting local policies.

Quantifying material sensitivity and near-term exposures (approximate and illustrative, based on latest public disclosures and market data):

• Regulatory mitigation: Maintaining diversified portfolio (innovatives, biologics, generics) and active engagement with regulators reduces single-product dependency but cannot eliminate approval risk.
• Hedging & FX controls: Treasury policies (forward cover, natural hedges) can limit short-term earnings volatility, yet residual exposure remains if international operations expand rapidly.
• Competition response: Pricing flexibility, local-market partnerships, and lifecycle management (line extensions, differentiated formulations) are important to defend margins.
• M&A integration playbook: Clear KPIs, retention packages for key talent, and alignment of compliance systems determine whether acquisitions like Imexpharm boost or drain shareholder value.

For deeper context on investor positioning and shareholding trends that interact with these risks, see: Exploring Livzon Pharmaceutical Group Inc. Investor Profile: Who's Buying and Why?

Livzon Pharmaceutical Group Inc. (1513.HK) - Growth Opportunities

Livzon Pharmaceutical Group Inc. (1513.HK) is positioning itself for multi-dimensional growth through strategic M&A, capital management, product innovation, technology adoption and geographic expansion. Key items that investors should weigh include the company's recent acquisition moves, shareholder-return initiatives, R&D emphasis on innovative and complex formulations, and adoption of AI-enabled drug development-each reinforcing the company's internationalization strategy and potential for sustainable earnings growth.

• Strategic acquisition: In May 2025 Livzon completed the acquisition of a 64.81% stake in Imexpharm Corporation, immediately opening access to Vietnam's fast-growing pharmaceutical market and distribution channels.
• Shareholder value signals: Ongoing share repurchase programs remain in effect, reducing outstanding float and signaling management confidence in intrinsic value and future cash-flow visibility.
• Product strategy: The company's explicit focus on "innovative drugs + high‑barrier complex formulations" targets therapeutic areas with unmet clinical needs and higher pricing/patent-protection potential relative to commoditized generics.
• AI integration: Piloting and scaling AI in biopharmaceutical R&D aims to shorten discovery timelines, improve candidate selection, and raise development success rates-boosting R&D efficiency and potentially lowering per-program costs.
• Internationalization: Expansion into regional markets (Vietnam via Imexpharm and other export channels) supports revenue diversification and long-term margin improvement from higher-value products.
• R&D commitment: Continued emphasis on internal innovation and pipeline diversification to maintain technological and regulatory barriers to entry.

• Investor implications: The Imexpharm acquisition accelerates near-term addressable market expansion in Southeast Asia while repurchase activity supports per-share metrics; sustained R&D and AI adoption aim to lift long-term product mix toward higher-margin innovative drugs.
• Operational levers to watch: integration progress in Vietnam (sales synergy, supply-chain consolidation), sequencing of AI-driven pipeline milestones, R&D spend cadence vs. clinical readouts, and the size/timing of future buybacks.

For more on Livzon's stated strategic direction and values, see: Mission Statement, Vision, & Core Values (2026) of Livzon Pharmaceutical Group Inc.